Advertisement

Search Results

Advertisement



Your search for Jo Cavallo matches 14 pages

Showing 1 - 14


lymphoma

Study Finds Increased Risk for Non-Hodgkin Lymphoma in HIV-Infected Patients

In the HIV-negative population, there is growing evidence suggesting that chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) are both associated with the development of non-Hodgkin lymphoma (NHL), although the mechanisms underlying this association remain unclear. The incidence rate of NHL ...

lymphoma

Higher Mortality Risk in Poor or Minority Adolescents and Young Adults vs White Patients With Hodgkin Lymphoma

Despite improvements in survival for adolescents and young adults diagnosed with Hodgkin lymphoma, the gains have not been shared uniformly across this patient population. A large population-based study by Keegan et al investigating the impact of race/ethnicity, socioeconomic status, influence of...

lymphoma
survivorship

Survivorship Symposium 2016: Study Finds That Less Than Half of Survivors of Hodgkin Lymphoma Received All Recommended Follow-up Care

According to the American Cancer Society’s 2014 Cancer Facts & Figures, Hodgkin lymphoma is diagnosed in about 800 adolescents and young adults each year. And while standard treatments for the cancer, including chemotherapy and radiation, are very effective in improving survival,...

lymphoma

Investigational NAE Inhibitor Pevonedistat Shows Potential Activity in Patients With Relapsed/Refractory Lymphoma

A phase I study evaluating the safety, pharmacokinetic profile, pharmacodynamic effects, and antitumor activity of the first-in-class investigational NEDD8-activating enzyme (NAE) inhibitor pevonedistat (TAK-924/MLN4924) in patients with relapsed/refractory lymphoma or multiple myeloma has found...

lymphoma

Lenalidomide Plus Rituximab Appears Promising as First-Line Therapy for Mantle Cell Lymphoma

Mantle cell lymphoma, which is characterized by CD5-positive, CD23-negative follicular mantle B cells with t(11:14)(q13;q32) translocation and cyclin D1 overexpression, is generally incurable and associated with a median survival of between 4 and 5 years. Although front-line treatment for mantle...

leukemia
lymphoma

Chemotherapy Pretreatment May Boost Effectiveness of CAR T-Cell Therapy in Patients With Lymphoma and Leukemia

A small phase I/IIa study of third-generation CD19 CAR (chimeric-antigen receptor) T-cell therapy combined with chemotherapy pretreatment has resulted in complete responses in 6 of the 11 patients with relapsed or refractory lymphoma and leukemia enrolled in the study. Although CAR T-cell...

lymphoma

Circulating Tumor DNA in Blood May Predict Recurrence in Patients With Diffuse Large B-Cell Lymphoma

A study assessing whether circulating tumor DNA encoding the clonal immunoglobulin gene sequence could be detected in the serum of patients with diffuse large B-cell lymphoma has found that surveillance circulating tumor DNA enabled detection of microscopic disease before it could be seen on CT...

lymphoma
issues in oncology

Survival of Patients With a Common Lymphoma Is Worse Among Those With Low Income

Despite advances in the treatment of diffuse large B-cell lymphoma (the most common subtype of non-Hodgkin lymphoma), including the introduction of rituximab (Rituxan), diffuse large B-cell lymphoma patients living in low-socioeconomic-status neighborhoods have a 34% greater risk of dying from...

hematologic malignancies
lymphoma

Results of Genomic Analysis Suggest Strategy for Overcoming Ibrutinib Resistance in Mantle Cell Lymphoma

Although the Bruton tyrosine kinase (BTK) inhibitor ibrutinib (Imbruvica) has shown unprecedented clinical activity in mantle cell lymphoma, about 32% of patients do not respond to the drug and majority of responders eventually relapse. Genomic sequencing of tumor and healthy tissue from patients...

hematologic malignancies
leukemia
lymphoma

Investigational Bromodomain Inhibitor Shows Clinical Activity in Some Blood Cancers

The results from a phase I study of a new investigational epigenetic therapy called OTX015, a small-molecule inhibitor that blocks the activity of bromodomain and extraterminal (BET)-bromodomain proteins, is showing clinical activity in some blood cancers, including leukemia and lymphoma. The study ...

lymphoma
survivorship

NCI Study Links Hodgkin Lymphoma Treatment to Risk of Stomach Cancer

Hodgkin lymphoma survivors who received subdiaphragmatic radiotherapy and chemotherapy regimens containing high doses of the alkylating agent procarbazine (Matulane) were at an increased risk of developing stomach cancer, according to a large study by scientists at the National Cancer Institute...

lymphoma

Risk for Lymphoma Increases in Celiac Patients With Persistent Villous Atrophy

Although celiac disease is associated with an increased risk of lymphoma, including enteropathy-associated T-cell lymphoma, it was not known whether persistent atrophy of the villi, the fingerlike projections that normally absorb nutrients, contributed to that risk. In a large population-based...

lymphoma

Predicting Risk of Treatment-related Mortality in Advanced-stage Hodgkin Lymphoma

Improvements in radiation therapy and the development of chemotherapy regimens, such as MOPP (mechlorethamine [Mustargen], vincristine, procarbazine [Matulane], and prednisone), and ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine), in the treatment of Hodgkin lymphoma have made the...

lymphoma

Survival Rates for Patients with Burkitt’s Lymphoma Improve, Especially among Young Adults

Although Burkitt’s lymphoma remains one of the most highly aggressive forms of B-cell non-Hodgkin lymphoma and is associated with human immunodeficiency virus (HIV) infection, a recent study published in Blood has found a marked improvement in patient survival over the past decade, especially ...

Advertisement

Advertisement



Advertisement